Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1035)	7/17/1998 10:38:00 AM
From: Ariella	Respond to of 1491

thomsoninvest.net This recommendation is based on recent insider buys, previoiusly noted on thread, but it's nice to see anyhow.

To: Ariella who wrote (1035)	7/17/1998 11:49:00 AM
From: NeuroInvestment	Read Replies (3) \| Respond to of 1491

1) I am told that the decrease in dosage was not due to any incipient adverse effects, which would have been the negative possibility> Gad Reisenfeld is not back in the US until next week, so my speculation regarding pharmacokinetic hypotheses is simply that; perhaps they are finding that there is a ceiling on how much HU211 actually is absorbed into the CNS, making a doubling of the dose superfluous. In that case, 200mg may be an attempt to make a finetuned differentiation of optimal dosing (whereas 150 vs 300 would have left too much gap 'in between') for Phase III). 2) Increasing the number of sites could allow them to increase the sample size if they are not sure the trends are strong enough in the cohorts done so far, it also could allow them to complete the trial faster if they stayed with the same N, thus allowing a Phase III to start earlier. 3) By the way, since there has been some confusion about the $900,000: this is gross (@29%) revenue from B&L. PARS must now send back monies to B&L as loan repayment, pay royalties to the inventor, and pay for the product. My rough calculation is that they get to keep $540,000 or so for themselves (900,000-(900,000*9%)-(900,000-31%). NeuroInvestment (www.neuroinv.com)